Obermeyer Wood Investment Counsel Lllp Has $574,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Obermeyer Wood Investment Counsel Lllp lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 4.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,185 shares of the biopharmaceutical company’s stock after acquiring an additional 450 shares during the period. Obermeyer Wood Investment Counsel Lllp’s holdings in Bristol-Myers Squibb were worth $574,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Norges Bank bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $1,873,696,000. Moneta Group Investment Advisors LLC raised its stake in Bristol-Myers Squibb by 114,228.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 21,469,785 shares of the biopharmaceutical company’s stock valued at $1,544,751,000 after purchasing an additional 21,451,006 shares in the last quarter. Pacer Advisors Inc. raised its stake in Bristol-Myers Squibb by 48.0% in the fourth quarter. Pacer Advisors Inc. now owns 7,830,948 shares of the biopharmaceutical company’s stock valued at $401,806,000 after purchasing an additional 2,540,360 shares in the last quarter. AustralianSuper Pty Ltd acquired a new position in Bristol-Myers Squibb during the fourth quarter worth about $86,965,000. Finally, Cowa LLC raised its stake in Bristol-Myers Squibb by 9,777.8% during the first quarter. Cowa LLC now owns 1,657,894 shares of the biopharmaceutical company’s stock worth $1,211,000 after acquiring an additional 1,641,110 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock traded up $0.46 on Thursday, hitting $48.30. 10,908,240 shares of the stock were exchanged, compared to its average volume of 15,781,828. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $97.89 billion, a PE ratio of 12.46, a P/E/G ratio of 1.49 and a beta of 0.39. Bristol-Myers Squibb has a one year low of $47.58 and a one year high of $70.93. The firm’s 50 day moving average is $51.26 and its two-hundred day moving average is $51.59.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter last year, the company earned $1.82 EPS. The firm’s revenue was up .6% compared to the same quarter last year. Sell-side analysts expect that Bristol-Myers Squibb will post 6.47 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 4.97%. Bristol-Myers Squibb’s dividend payout ratio is currently 62.18%.

Analysts Set New Price Targets

Several research firms have recently weighed in on BMY. Wells Fargo & Company boosted their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Bank of America cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their target price for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $61.18.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.